T

op of the morning to you, and a fine one, it is. A sunny sky and a cool breeze are enveloping the cozy Pharmalot campus, where the usual routine was briefly altered when the short person required extra help reaching the local schoolhouse. Now, though, the rhythm has returned as we forage for items of interest. Speaking of which, here are some tidbits to help you along during what is likely to be a busy day, yes? So grab your cup of stimulation and dig in. Hope all goes well and do keep in touch. We enjoy hearing and reading secrets …

Shire (SHPG) filed an antitrust lawsuit accusing Allergan (AGN) of using contracts with Medicare Part D plans to block access to its Xiidra eye drops, which compete with Allergan’s Restasis drops. “We do not see how Allergan‘s discounting and rebating is different from the normal course of action in the pharmaceutical industry,” Wells Fargo analyst David Maris writes. “These allegations are very common,” Herbert Hovenkamp, an antitrust expert at the University of Pennsylvania, tells The Wall Street Journal. “They are not easy to prove.”

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy